Skip to main content

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Completed · Phase 1 · NCT06834789

Conditions: Glabellar Lines

At a glance

Research payments reported, 2025
$3.4M
U.S. investigators named
8
Sites paid
10
Planned or actual enrollment
132

About the trial

Sponsor
AbbVie
Tested
AGN-151586 (drug), OnabotulinumtoxinA (drug), Placebo (drug)
Dates
Started 2025-02-18; completion 2025-11-03
Results posted
Not yet

The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).

From ClinicalTrials.gov, last updated 2025-11-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $3.4M in research payments for this study in 2025 (66 payments).

Products named: Botox

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Eye Research Foundation Inc $613,462
  • Wdc Cosmetic and Research PLLC $543,527
  • Pflugerville Dermatology Clinical $479,941
  • Keith A Marcus MD Inc $464,893
  • Investigate MD LLC $379,919
  • Skincare Physicians Inc $339,675
  • Skin Research Institute LLC $328,515
  • Skin Dc PLLC $205,901
  • Skincare Physicians $2,178
  • Marcus Facial Plastic Surgery $2,178

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.